Edition:
United Kingdom

Daiichi Sankyo, AstraZeneca Announce Global Development, Commercialization Collaboration For Trastuzumab Deruxtecan (Ds-8201)


Thursday, 28 Mar 2019 

March 29 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO AND ASTRAZENECA ANNOUNCE GLOBAL DEVELOPMENT AND COMMERCIALIZATION COLLABORATION FOR DAIICHI SANKYO'S HER2 TARGETING ANTIBODY DRUG CONJUGATE FAM- TRASTUZUMAB DERUXTECAN (DS-8201).ASTRAZENECA TO PAY DAIICHI SANKYO UP TO $6.90 BILLION IN TOTAL CONSIDERATION.DAIICHI SANKYO -CO AND ASTRAZENECA TO SHARE EQUALLY DEVELOPMENT AND COMMERCIALIZATION COSTS,PROFITS WORLDWIDE FROM FAM- TRASTUZUMAB DERUXTECAN.ASTRAZENECA'S TOTAL PAYMENT TO DAIICHI SANKYO INCLUDES UPFRONT PAYMENT OF $1.35 BILLION.DAIICHI SANKYO - CO, ASTRAZENECA TO JOINTLY DEVELOP, COMMERCIALIZE TRASTUZUMAB DERUXTECAN AS MONOTHERAPY, COMBINATION THERAPY WORLDWIDE, EXCEPT JAPAN.DAIICHI SANKYO WILL BE SOLELY RESPONSIBLE FOR MANUFACTURING AND SUPPLY OF FAM- TRASTUZUMAB DERUXTECAN.IMPACT ON DAIICHI SANKYO'S CONSOLIDATED RESULTS FOR FISCAL YEAR ENDING MARCH 31, 2019 IS IMMATERIAL.DAIICHI SANKYO - CO, ASTRAZENECA TO SHARE EQUALLY DEVELOPMENT, COMMERCIALIZATION COSTS, PROFITS FROM TRASTUZUMAB DERUXTECAN WORLDWIDE, EXCEPT JAPAN.DAIICHI SANKYO- CO EXPECTED TO BOOK SALES IN U.S., CERTAIN COUNTRIES IN EUROPE, CERTAIN OTHER MARKETS WHERE DAIICHI SANKYO HAS AFFILIATES.ASTRAZENECA IS EXPECTED TO BOOK SALES IN ALL OTHER MARKETS WORLDWIDE, INCLUDING CHINA, AUSTRALIA, CANADA AND RUSSIA.